| Application no. and date | 18155644.0 (espacenet) (Federated) (European Patent Register), 20020218 | | Patent/reg. no. and date | DK/EP 3351246, 20190522 | | Publication date | 20180725 | | Priority no. and date | GB 0104072, 20010219, GB 0124957, 20011017 | | EP pub. no. and date |
EP 3351246 20180725 | | Effective date | | | Applicant/owner | Novartis Pharma AG, Lichtstrasse 35
4002 Basel, CH | | Applicant ref. no. | 158913 SH/GP | | Inventor | Wood, Jeanette Marjorie, In den Kleematten 18
4105 Biel-Benken, CH,
Lane, Heidi, Kaltbrunnenweg 8
4106 Therwill, CH,
O`Reilly, Terence, Drahtzugstrasse 51
4057 Basel, CH | | Representative | Budde Schou A/S, Dronningens Tværgade 30, 1302 København K | | Opponent | | | IPC Class | A61K 31/436 (2006.01) , A61P 35/00 (2006.01) , A61P 35/04 (2006.01) | | Title | Rapamycinderivat til behandling af en solid tumor, som er associeret med dereguleret angionese | | Int. application no. | | | Int. publication no. | | | Related patent (certificate) | CA 2019 00056 | | Status | Ophævet | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
